Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection.
AB0 blood groups
COVID-19
SARS-CoV-2
antibodies
blood donation
long-COVID
seroprevalence
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
18 03 2022
18 03 2022
Historique:
received:
02
03
2022
revised:
14
03
2022
accepted:
17
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
1
4
2022
Statut:
epublish
Résumé
The developmental course of antibodies produced after a SARS-CoV-2 infection has been insufficiently investigated so far. Therefore, the aim of this study was to investigate the dynamics of SARS-CoV-2 antibody levels against the viral nucleocapsid- and spike-protein among Austrian blood donors as a representative group of a supposedly healthy population within the first year after a SARS-CoV-2 infection. The impact of age, sex, vaccination status, AB0-blood group and awareness about the infection was evaluated. Our study shows that the level of anti-N antibodies is declining, while anti-S antibody levels remain stable. Antibodies detected were functional in vitro. Age, sex and blood group do not influence antibody dynamics. However, blood group AB shows significantly lower antibody levels and in vitro functionality compared to other blood groups. Our data reveal that one out of five individuals was not aware of a previous SARS-CoV-2 infection and that the disease course neither affects the level of antibody production nor the in vitro functionality. We also found that 14% of participants show persisting COVID-19-related symptoms for up to nine months. Our results provide valuable insights into the dynamics of the immune response after a SARS-CoV-2 infection in a representative cohort of adult blood donors in Central Europe.
Identifiants
pubmed: 35337044
pii: v14030637
doi: 10.3390/v14030637
pmc: PMC8953712
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Paracelsus Medical University
ID : 20204-WISS/225/197-2019
Organisme : Paracelsus Medical University
ID : 20102-F1901166-KZP
Références
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
Front Immunol. 2021 Jun 16;12:708523
pubmed: 34220870
Semin Vasc Surg. 2021 Sep;34(3):125-131
pubmed: 34642032
Nat Commun. 2020 Nov 13;11(1):5761
pubmed: 33188185
Lancet Healthy Longev. 2022 Jan;3(1):e13-e21
pubmed: 34935001
Pathogens. 2021 Jun 17;10(6):
pubmed: 34204243
Sci Rep. 2021 Dec 1;11(1):23216
pubmed: 34853374
Ann Intern Med. 2021 Mar;174(3):308-315
pubmed: 33226859
Blood Adv. 2020 Oct 27;4(20):4981-4989
pubmed: 33057633
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Emerg Infect Dis. 2021 Apr;27(4):1155-1158
pubmed: 33734962
Br J Haematol. 2020 Jul;190(1):24-27
pubmed: 32379894
Open Forum Infect Dis. 2021 Jul 15;8(8):ofab378
pubmed: 34395713
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
Blood Adv. 2020 Oct 27;4(20):4990-4993
pubmed: 33057631
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Vaccines (Basel). 2021 Oct 18;9(10):
pubmed: 34696303
Nat Rev Immunol. 2022 Jan;22(1):57-65
pubmed: 34876702
Immunohorizons. 2021 Jun 17;5(6):466-476
pubmed: 34398806
Front Public Health. 2021 Jan 15;8:582932
pubmed: 33520910
Infection. 2021 Dec;49(6):1187-1194
pubmed: 34132990
Signal Transduct Target Ther. 2021 Nov 9;6(1):387
pubmed: 34753918
Chin Med J (Engl). 2021 Dec 13;135(2):145-152
pubmed: 34908003
Transfus Apher Sci. 2021 Dec;60(6):103224
pubmed: 34366234
Int J Infect Dis. 2021 Mar;104:242-249
pubmed: 33326874
Lancet Healthy Longev. 2021 Dec;2(12):e811-e819
pubmed: 34873592
Nat Commun. 2021 Oct 29;12(1):6250
pubmed: 34716320
Ann Hematol. 2020 Sep;99(9):2113-2118
pubmed: 32656591
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Transfusion. 2020 Aug;60(8):1883-1884
pubmed: 32562280
J Chin Med Assoc. 2021 Jan 1;84(1):3-8
pubmed: 33230062
J Clin Virol. 2020 Aug;129:104540
pubmed: 32652475
JAMA. 2021 Oct 12;326(14):1400-1409
pubmed: 34473201
Br J Haematol. 2020 Aug;190(4):e204-e208
pubmed: 32609874
PLoS One. 2021 Nov 2;16(11):e0250541
pubmed: 34727115
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Med Virol. 2021 Dec;93(12):6486-6495
pubmed: 34264528
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
Ann Med Surg (Lond). 2021 Dec;72:103130
pubmed: 34900250
Rev Med Virol. 2022 Jan;32(1):e2247
pubmed: 34997677
J Infect Public Health. 2020 Nov;13(11):1601-1610
pubmed: 32778421
Neuroimage. 2020 May 15;212:116672
pubmed: 32092432
Haematologica. 2020 Jul 23;105(12):2841-2843
pubmed: 33256383
Front Immunol. 2021 Nov 03;12:772239
pubmed: 34804064
Rev Med Virol. 2021 Mar;31(2):e2162
pubmed: 32964627
Front Microbiol. 2022 Jan 05;12:799519
pubmed: 35069504
J Neuroimmune Pharmacol. 2020 Sep;15(3):359-386
pubmed: 32696264
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508